Role of gelatinases (matrix metalloproteinases 2 and 9), vascular endothelial growth factor and endostatin on clinicopathological behaviour of rectal cancer

Colorectal Disease

Volumn 13, Issue 2, 2011, Pages 154-160

  Cavdar, Z ^a   Canda, A E ^a   Terzi, C ^a   Sarioglu, S ^a   Fuzun, M ^a   Oktay, G ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Endostatin; Matrix metalloproteinase 2; Matrix metalloproteinase 9; Rectal cancer; Vascular endothelial growth factor

Indexed keywords

ENDOSTATIN; GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; PERINEURIUM; PRIORITY JOURNAL; PROGNOSIS; RECTUM CANCER; RECTUM SURGERY; ZYMOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; ENDOSTATINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROGNOSIS; RECTAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78751690198     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/j.1463-1318.2009.02105.x     Document Type: Article

References (47)

1. Morelli D, Lazzerini D, Cazzaniga S. Evaluation of the balance between angiogenic and antiangiogenic circulating factors in patients with breast and gastrointestinal cancers. Clin Cancer Res 1998; 4: 1221-5.
2. Xie K, Wei D, Shi Q, Huang S. Constitutive and inducible expression and regulation of vascular endothelial growth factor. Cytokine Growth Factor Rev 2004; 15: 297-324.
3. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumour growth. Cell 1997; 88: 277-85.
4. Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 1999; 103: 1237-41.
5. Seiki M, Yana I. Roles of percellular proteolysis by membrane type-I matrix metalloproteinases in cancer invasion and angiogenesis. Cancer Sci 2003; 94: 569-74.
6. Barrantes HS, Toth M, Bernardo M, Yurkova M, Gervasi DC, Raz Y, Sang QA, Fridman R. Binding of active (57kDa) membrane type1-matrix metalloproteinase (MT1-MMP) to tissue inhibitor of metalloproteinase (TIMP-2) regulates MT1-MMP processing and pro-MMP-2 activation. J Biol Chem 2000; 275: 12080-9.
7. Zucker S, Jeffrey V. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev 2004; 23: 101-17.
8. Mook ORF, Frederiks WM, Noorden CJF. The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta 2004; 1705: 69-89.
9. Bergers G, Brekken R, McMahon G et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2: 737-44.
10. Ferreras M, Felbor U, Lenhard T, Olsen BR, Delaisse J. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett 2000; 486: 247-51.
11. Paddenberg R, Faulhammer P, Goldenberg A, Kummer W. Hypoxia induces increase of endostatin in murine aorta and lung. Histochem Cell Biol 2006; 125: 497-508.
12. Morimoto T, Aoyagi M, Tamaki M et al. Increased levels of tissue endostatin in human malignant gliomas. Clin Cancer Res 2002; 8: 2933-8.
13. Wiechelman KJ, Braun RD, Fitzpatrek JD. Investigation of bicinchoninic acid protein assay: identification of the groups responsible for color formation. Anal Biochem 1988; 175: 231-7.
14. Kleiner DE, Stetler-Stevenson WG. Quantitative zymography: detection of picogram quantities of gelatinases. Anal Biochem 1994; 218: 325-9.
15. Ornestein DL, Cohn KH. Balance between activation and inhibition of matrix metalloproteinase-2 (MMP-2) is altered in colorectal tumours compared to normal colonic epithelium. Dig Dis Sci 2002; 47: 1821-30.
16. Pesta M, Holubec L Jr, Topolcan O et al. Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples. Anticancer Res 2005; 25: 3387-91.
17. Collins HM, Morris TM, Watson SA. Spectrum of matrix metalloproteinase expression in primary and metastatic colon cancer: relationship to the tissue inhibitors of metalloproteinases and membrane type-1-matrix metalloproteinase. Br J Cancer 2001; 84: 1664-70.
18. Baker EA, Bergin FG, Leaper DJ. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging. Br J Surg 2000; 87: 1215-21.
19. Moran A, Iniesta P, Garcia-Aranda C, De Juan C, Diaz-Lopez A, Sanches-Pernaute A, Torres AJ, Diaz-Rubio E, Balibrea JL, Benito M. Clinical relevance of MMP-9, MMP-2, TIMP-1 and TIMP-2 in colorectal cancer. Oncol Rep 2005; 13: 115-20.
20. Heslin MJ, Yan J, Johnson MR, Weiss H, Diasio RB, Urist MM. Role of matrix metalloproteinases in colorectal carcinogenesis. Ann Surg 2001; 233: 786-92.
21. Pesta M, Holubec L Jr, Topolcan O, Cerna M, Rupert K, Holubec LS, Treska V, Finek J, Cerny R. Clinicopathological assessment and quantitative estimation of matrix metalloproteinases MMP-2 and MMP-7 and inhibitors TIMP-1 and TIMP-2 in colorectal carcinoma tissue samples. Anticancer Res 2007; 27: 1863-8.
22. Tutton MG, George ML, Eccles SA, Burton S, Swift RI, Abulafi AM. Use of plasma MMP-2 and MMP-9 levels as a surrogate for tumour expression in colorectal cancer patients. Int J Cancer 2003; 107: 541-50.
23. Sis B, Sagol O, Kupelioglu A, Sokmen S, Terzi C, Fuzun M, Ozer E, Bishop P. Prognostic significance of matrix metalloproteinase-2, cathepsin D, and tenascin-C expression in colorectal carcinoma. Pathol Res Pract 2004; 200: 379-87.
24. Islekel H, Oktay G, Terzi C, Canda AE, Fuzun M, Kupelioglu A. Matrix metalloproteinase-9, -3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables. Cell Biochem Funct 2007; 25: 433-41.
25. Waas ET, Lome RM, DeGroot J, Wobbes TH, Hendriks T. Tissue levels of active matrix metalloproteinase-2 and -9 in colorectal cancer. Br J Cancer 2002; 86: 1876-83.
26. Hilska M, Roberts PJ, Collan YU, Laine VJ, Kössi J, Pirkko H, Rahkonen O, Laato M. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. Int J Cancer 2007; 121: 714-713.
27. Ngan CY, Yamamoto H, Seshimo I, Ezumi K, Terayama M, Hemmi H, Takemasa I, Ikeda M, Sekimoto M, Monden M. A multivariate analysis of adhesion molecules expression in assessment of colorectal cancer. J Surg Oncol 2007; 95: 652-62.
28. Schwander OA, Schlamp R, Broll H, Bruch P. Clinicopathologic and prognostic significance of matrix metalloproteinases in rectal cancer. Int J Colorectal Dis 2007; 22: 127-36.
29. Unsal D, Uner A, Akyurek N, Erpolat P, Dursun A, Pak Y. Matrix metalloproteinase-9 expression correlated with tumour response in patients with locally advanced rectal cancer undergoing preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys 2007; 67: 196-203.
30. Kapitejin E, Liefers GJ, Los LC, Kranenbarg EK, Hermans J, Tollenaar RA, Moriya Y, Velde CJH, Krieken JH. Mechanisms of oncogenesis in colon versus rectal cancer. J Pathol 2001; 195: 171-8.
31. Konishi K, Fujii T, Boku N, Kato S, Koba I, Ohtsu A, Tajiri H, Ochiai A, Yoshida S. Cinicopathological differences between colonic and rectal carcinomas: are they based on the same mechanism of carcinogenesis? Gut 1999; 45: 818-21.
32. Kim TD, Song KS, Li G, Choi H, Park HD, Lim K, Hwang BD, Yoon WH. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer. BMC Cancer 2006; 18: 211-21.
33. Roeb E, Dietrich CG, Winograd R, Arndt M, Breuer B, Fass J, Schumpelick V, Matern S. Activity and cellular origin of gelatinases in patients with colon and rectal carcinoma. Cancer 2001; 92: 2680-91.
34. McCawley LJ, Matrisian LM. Matrix metalloproteinases: multifunctional contributors to tumour progression. Mol Med Today 2000; 6: 149-56.
35. Lamoreaux WJ, Fitzgerald MEC, Reiner A, Hasty KA, Charles ST. Vascular endothelial growth factor increases release of gelatinase A and decrease release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc Res 1998; 55: 29-42.
36. Garcia AG, Rodriquez AS, Jimenez A, Blanco AP, Perez DN, Cabrera C, Gonzalez FD, Medina C, Flores LD. Up-regulation of gelatinases in the colorectal adenoma-carcinoma sequence. Eur J Cancer 2006; 42: 3246-52.
37. Kim YM, Jang JW, Lee OH, Yeon J, Choi EY, Kim KW, Lee ST, Kwon YG. Endostatin inhibits endothelial and tumour cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase 2. Cancer Res 2000; 60: 5410-3.
38. Sounni NE, Noel A. Membrane type-matrix metalloproteinases and tumour progression. Biochimie 2005; 87: 329-42.
39. Malhotra S, Newman E, Eisenberg D, Scholes J, Wieczorek R, Mignatti P, Shammamian P. Increased membrane type 1 matrix metalloproteinase expression from adenoma to colon cancer: a possible mechanism of neoplastic progression. Dis Colon Rectum 2002; 45: 537-42.
40. Bendardaf R, Lamlum H, Vihinen P, Ristamaki R, Laine J, Pyrhonen S. Low collagenase-1 (MMP-1) and MT1-MMP expression levels are favourable survival markers in advanced colorectal carcinoma. Oncology 2003; 65: 337-46.
41. Bigg HF, Morrison CJ, Butler GS, Bugoyevitch MA, Soloway PD, Overall CM. Tissue inhibitor of metalloproteinases-4 inhibits but does not support the activation of gelatinase A via efficient inhibition of membrane type 1-matrix metalloproteinase. Cancer Res 2001; 61: 3610-8.
42. Lii BH, Zhao P, Liu SZ, Yu YM, Han M, Wen JK. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in colorectal carcinoma invasion and metastasis. World J Gastroenterol 2005; 11: 3046-50.
43. Giralt J, Navalpotro B, Hermosilla E et al. Prognostic significance of vascular endothelial growth factor and cyclooxygenase-2 in patients with rectal cancer treated with preoperative radiotherapy. Oncology 2006; 71: 312-9.
44. Yang D, Schneider S, Azuma M et al. Gene expression levels of epidermal growth factor receptor, survivin, and vascular endothelial growth factor as molecular markers of lymph node involvement in patients with locally advanced rectal cancer. Clin Colorectal Cancer 2006; 6: 305-11.
45. Brammer RD, Bramhall SR, Eggo MC. Endostatin expression in pancreatic tissue is modulated by elastase. Br J Cancer 2004; 92: 89-93.
46. Schmidt A, Sommer F, Reiner M, Klotz T, Engelmann U, Addicks K, Bloch W. Differential endostatin binding to bladder, prostate and kidney tumour vessels. BJU Int 2005; 95: 174-9.
47. Ratel D, Nasser V, Dupre I, Benabid AL, Berger F. Antibodies to endostatin in a multifocal glioblastoma patient. Lancet 2000; 356: 1656-7.